Loading organizations...
§ Public · Menlo Park, CA, USA
Grail is a technology company.
GRAIL is a healthcare company that develops multi-cancer early detection tests from a single blood sample. Its core product identifies cancer signals in asymptomatic individuals, leveraging high-intensity sequencing and advanced computational science to detect molecular changes indicative of cancer. The company’s technology aims to provide comprehensive screening through a non-invasive method.
GRAIL was founded in 2015, emerging from an insight at Illumina regarding the application of next-generation sequencing to transform cancer detection. Key figures in its establishment include founding CEO Jeff Huber and Mostafa Ronaghi, who envisioned a blood-based test capable of catching cancer at its most curable stages. Huber's prior executive experience significantly shaped the company's early trajectory.
The company's products serve healthcare providers and their patients, facilitating proactive screening for various cancer types. GRAIL’s mission centers on significantly reducing cancer mortality by enabling early detection, thereby improving treatment outcomes and ultimately changing the trajectory of cancer care for millions.
Grail has raised $1.1B across 5 funding rounds.
Key people at Grail.
Grail has raised $1.1B in total across 5 funding rounds.
Grail has raised $1.1B across 5 funding rounds. Most recently, it raised $50.0M Series D in April 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Apr 7, 2024 | TODAY | $5.0M Seed | SAM KIM, DAN Patterson | Dingaling, Tommy Tran, 32 BIT Ventures, Builder Capital, Collab+Currency, GSR, Lingfeng Innovation Fund, Metavest Capital, Spirit DAO |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2020 | $50M Series D | — | Arboretum Ventures, Baird Capital, Endeavor Venture Funds, Illumina, PSP Investments | Announced |
| Apr 1, 2018 | $50M Series C | Frank YU | Arboretum Ventures, Baird Capital, Endeavor Venture Funds, Lifetech Scientific | Announced |
| Mar 1, 2017 | $900M Series B | ARCH Venture Partners | Johnson & Johnson Innovation | Announced |
| Jan 1, 2016 | $100M Series A | — | ARCH Venture Partners, Triatomic Capital, Venrock, Bill Gates, Jeff Bezos, Sutter Hill Ventures | Announced |
| Dec 1, 2015 | $15M Series A | — | Arboretum Ventures, Baird Capital, Endeavor Venture Funds, Triatomic Capital | Announced |
Key people at Grail.
GRAIL is a biotechnology company pioneering multi-cancer early detection (MCED) technology through its flagship Galleri blood test, which detects signals from over 50 cancer types—many lacking standard screening—via a single draw analyzing cell-free DNA (cfDNA) methylation patterns.[1][2][3] It serves individuals at elevated risk, such as those aged 50+, by identifying cancer early (before symptoms) and predicting its origin (e.g., lungs, colon) with low false positives (<1%), complementing existing screenings to potentially avert 39% of cancer deaths within five years.[1][3][4] Recent growth includes positive top-line results from the PATHFINDER 2 registrational study (June 2025), showing higher cancer detection and positive predictive value than prior studies, with FDA PMA submission expected in H1 2026.[4]
GRAIL emerged in 2015 from Illumina's research breakthrough: repeated sequencing of bloodstream DNA enabled accurate detection of cancer cell fragments, sparking the company as a San Francisco biotech startup under Illumina (San Diego).[1][6][7] Key advocate Richard Klausner, Illumina's chief medical officer and ex-National Cancer Institute director, drove its formation, assembling scientists, engineers, and physicians to leverage next-generation sequencing (NGS), population-scale studies, and machine learning against cancer's challenges.[1][7] Pivotal moments include Galleri's 2021 launch, massive trials (>385K participants, >300 publications), and a 2024 spin-off from Illumina mandated by EU regulators, marking independence amid over 12 petabytes of data generated.[2][3][6][7]
GRAIL rides the convergence of genomics, NGS, AI/machine learning, and big data to shift cancer care from late-stage treatment to population-scale early detection, addressing a market where most cancers (e.g., esophageal, liver) evade screening.[1][2][5] Timing aligns with post-pandemic health tech acceleration and regulatory tailwinds like FDA Breakthrough Designation, amplified by 2025 PATHFINDER 2 data boosting MCED credibility.[4] It influences ecosystems via partnerships with health systems/academic centers, massive datasets enhancing cancer biology insights, and potential to integrate with precision oncology, reducing global cancer burden.[2][4][6]
GRAIL's PATHFINDER 2 momentum positions Galleri for FDA PMA completion by mid-2026, enabling broader U.S. adoption and global expansion amid rising MCED demand.[4] Trends like AI-driven genomics, liquid biopsies, and personalized risk screening will propel growth, though reimbursement and competition loom. Its influence may evolve from pioneer to standard-of-care integrator, tying back to its core mission: detecting cancer early, when it can be cured, potentially transforming millions of lives.[1][5]
Grail has raised $1.1B in total across 5 funding rounds.
Grail's investors include Arboretum Ventures, Baird Capital, Endeavor Venture Funds, Illumina, PSP Investments, Frank Yu, Lifetech Scientific, ARCH Venture Partners, Johnson & Johnson Innovation, Triatomic Capital, Venrock, Bill Gates.